Trials / Withdrawn
WithdrawnNCT03316729
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects With Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care. Evaluation will be done with low, medium and then high doses of DS-9231 versus placebo, in participants with medium-risk acute pulmonary embolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DS-9231 | DS-9231 in saline solution for intravenous infusion |
| DRUG | Placebo | Placebo is matching saline solution for intravenous infusion |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2020-02-01
- Completion
- 2020-02-01
- First posted
- 2017-10-20
- Last updated
- 2018-12-24
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03316729. Inclusion in this directory is not an endorsement.